Weinshenker BG - Search Results

1

Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD.

Cree BA, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk D, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Williams IM, Drappa J, She D, Cimbora D, Rees W, Ratchford JN, Katz E. Cree BA, et al. Among authors: weinshenker bg. Mult Scler. 2021 Nov;27(13):2052-2061. doi: 10.1177/1352458521988926. Epub 2021 Feb 4. Mult Scler. 2021. PMID: 33538237 Free PMC article. Clinical Trial.

2

Genetic variation in the tumor necrosis factor alpha gene and the outcome of multiple sclerosis.

Weinshenker BG, Wingerchuk DM, Liu Q, Bissonet AS, Schaid DJ, Sommer SS. Weinshenker BG, et al. Neurology. 1997 Aug;49(2):378-85. doi: 10.1212/wnl.49.2.378. Neurology. 1997. PMID: 9270565

3

A population-based case-control study of the tumor necrosis factor alpha-308 polymorphism in multiple sclerosis.

Wingerchuk D, Liu Q, Sobell J, Sommer S, Weinshenker BG. Wingerchuk D, et al. Among authors: weinshenker bg. Neurology. 1997 Aug;49(2):626-8. doi: 10.1212/wnl.49.2.626. Neurology. 1997. PMID: 9270614

4

Clinical outcome measures and rating scales in multiple sclerosis trials.

Wingerchuk DM, Noseworthy JH, Weinshenker BG. Wingerchuk DM, et al. Among authors: weinshenker bg. Mayo Clin Proc. 1997 Nov;72(11):1070-9. doi: 10.4065/72.11.1070. Mayo Clin Proc. 1997. PMID: 9374984 Review.

5

Genetic variants in the tumor necrosis factor receptor 1 gene in patients with MS.

Weinshenker BG, Hebrink D, Wingerchuk DM, Klein CJ, Atkinson E, O'Brien PC, McMurray CT. Weinshenker BG, et al. Neurology. 1999 Apr 22;52(7):1500-3. doi: 10.1212/wnl.52.7.1500. Neurology. 1999. PMID: 10227645

6

The clinical course of neuromyelitis optica (Devic's syndrome).

Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. Wingerchuk DM, et al. Among authors: weinshenker bg. Neurology. 1999 Sep 22;53(5):1107-14. doi: 10.1212/wnl.53.5.1107. Neurology. 1999. PMID: 10496275

7

The natural history of multiple sclerosis: implications for trial design.

Wingerchuk DM, Weinshenker BG. Wingerchuk DM, et al. Among authors: weinshenker bg. Curr Opin Neurol. 1999 Jun;12(3):345-9. doi: 10.1097/00019052-199906000-00013. Curr Opin Neurol. 1999. PMID: 10499179 Review.

8

Multiple sclerosis: epidemiology, genetics, classification, natural history, and clinical outcome measures.

Wingerchuk DM, Weinshenker BG. Wingerchuk DM, et al. Among authors: weinshenker bg. Neuroimaging Clin N Am. 2000 Nov;10(4):611-24 ,vii. Neuroimaging Clin N Am. 2000. PMID: 11359715 Review.

9

A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica.

Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, Trebst C, Weinshenker B, Wingerchuk D, Parisi JE, Lassmann H. Lucchinetti CF, et al. Brain. 2002 Jul;125(Pt 7):1450-61. doi: 10.1093/brain/awf151. Brain. 2002. PMID: 12076996 Free PMC article.

10

Neuromyelitis optica: clinical predictors of a relapsing course and survival.

Wingerchuk DM, Weinshenker BG. Wingerchuk DM, et al. Among authors: weinshenker bg. Neurology. 2003 Mar 11;60(5):848-53. doi: 10.1212/01.wnl.0000049912.02954.2c. Neurology. 2003. PMID: 12629245

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

365 results

Search Page

Filters